Get started
Author

Weiguo Su

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial
2018 · Jin Li, Shukui Qin, et al. · JAMA · 442
PDF
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
2021 · Shun Lu, Jian Fang, et al. · The Lancet Respiratory Medicine · 220
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
2020 · Jianming Xu, Lin Shen, et al. · The Lancet Oncology · 215
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
2020 · Jianming Xu, Lin Shen, et al. · The Lancet Oncology · 206
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
2014 · Qiaoling Sun, Jinghong Zhou, et al. · Cancer Biology & Therapy · 168
PDF
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer
2014 · Hong Jia, Guangxiu Dai, et al. · Journal of Medicinal Chemistry · 144
Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models
2014 · Paul R. Gavine, Yongxin Ren, et al. · Molecular Oncology · 125
PDF
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
2017 · Rui-Hua Xu, Jin Li, et al. · Journal of Hematology & Oncology · 95
PDF
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
2019 · Jianming Xu, Jie Li, et al. · Clinical Cancer Research · 83
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
2016 · Junning Cao, Jian Zhang, et al. · Cancer Chemotherapy and Pharmacology · 77
Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).
2020 · Shun Lu, Jian Fang, et al. · Journal of Clinical Oncology · 71
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
2022 · Ye Guo, Weijie Zhang, et al. · European Journal of Cancer · 69
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
2019 · Hui K. Gan, Michael Millward, et al. · Clinical Cancer Research · 69
Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
2014 · Yi Gu, Jian Wang, et al. · Cancer Chemotherapy and Pharmacology · 47
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
2024 · Feng Wang, Lin Shen, et al. · Nature Medicine · 44
Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial
2020 · Jiaying Chen, Qinghai Ji, et al. · Thyroid · 40
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
2024 · Yongfeng Yu, Qisen Guo, et al. · The Lancet Respiratory Medicine · 39
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
2016 · Ryan E. Henry, Evan R. Barry, et al. · Oncotarget · 39
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
2024 · Yu Hu, Xiaofan Liu, et al. · The Lancet Haematology · 37
A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer
2021 · Jianming Xu, Yuxian Bai, et al. · Cancer · 36
PDF
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
2022 · Shun Lu, Jian Fang, et al. · JTO Clinical and Research Reports · 33
Abstract CT031: Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations
2019 · Shun Lu, Jian Fang, et al. · Cancer Research · 33
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer
2018 · Shun Lu, Jianhua Chang, et al. · Journal of Clinical Oncology · 29
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
2024 · Panpan Zhang, Si Shi, et al. · European Journal of Cancer · 27
PDF
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
2023 · Xiaofan Liu, Hu Zhou, et al. · The Lancet Haematology · 27
Works count: 145
Citation count: 2,976
H-index: 26
I10-index: 44
Year
Topic
Type